Our investigation into OTUD3, along with its inhibitor rupatadine, has shown potential for offering innovative therapeutic choices in the field of targeted therapy and immunotherapy for patients with relapsed or refractory DLBCL [17]. This evidence concerns the gene OTUD3 and diffuse large B-cell lymphoma.